Citi Pharma dips its toes into veterinary medicine

In a significant development within Pakistan's pharmaceutical sector, Citi Pharma Limited (CPHL) has announced its foray into the veterinary healthcare market through its wholly owned subsidiary, Citi Veterinary Limited (CVL). This strategic move not only diversifies Citi Pharma's portfolio but also signals a growing recognition of the importance of animal health in the country.

Entering pet care

On September 12, 2025, Citi Pharma disclosed to the Pakistan Stock Exchange that CVL has commenced operations, launching an initial lineup of 32 veterinary products, including vaccines. The company has already established Letters of Credit (LCs) for eight of these products to ensure timely availability and supply. For the fiscal year 2025-26, CVL projects a turnover of approximately PKR 1.5 billion, with a gross profit margin of 13%. Looking ahead, the company aims to scale operations and achieve a turnover target of PKR 10 billion within the next three years.